Regulated information

Sales at end september 2025

9-month sales: €384 million (-1.3% at constant exchange rates and -3.5% on a reported basis)
9-month sales of Essential products: €244 million (64% of sales, +2.7% at constant exchange rates and +1.1% on a reported basis)

2025 Half-Year Results

Sales: €258m (-1.0% at constant exchange rates)
Essential products sales: €165m (+4.2% at constant exchange rates)
Net income, Group share: €25m (9.7% of sales)
EBITDA: €53m (20.4% of sales)
Cash flow generation: €51m

2025 Half-Year Results

Contents:
01. Activity for the first half of 2025
02. Consolidated results for the first half of 2025
03. Strategy and outlook

2024 Annual results

Annual sales: €539m (+2.2% at constant exchange rates)
Essential products sales: €328m (+4.6% at constant exchange rates)
Net result, Group share: €59m (10.9% of sales)
EBITDA: €104m (19.3% of sales)
Cash flow generation: €86m

SALES FOR 1ST QUARTER 2025

First-quarter sales of Essential products totaled 85 million euros, up+ 1.8% at constant exchange rates.

Annual sales 2024: €539 million

Annual sales: €539 million (up 2.2% at constant exchange rates and up 1.9%. on a reported basis)
Annual sales of Essential products: €328 million (up 4.6% at constant exchange rates and on a reported basis)

Sales at end September 2024

At the end of September 2024, Vetoquinol sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates.

2024 half-year Results

Sales: €264m (+3.2% as reported)
Essentials products sales: €160m (+6.0% of Group sales)
Net income - Group share: €24m (9.0% of sales)
EBITDA*: €45m (17% of sales)
Cash-flow generation: €27m

2024 Half-Year Results slideshow

Contents
1. First semester 2024 results
2. Conclusion and outlook

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m